ELISE BALLARD: Open Payments
NPI 1275385361 · MERRILLVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,613 in 59 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $5,389 · 2025 $4,613
Consulting: $3,094Food & beverage: $1,519
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 6 | $3,222 |
| Otsuka America Pharmaceutical, Inc. | 11 | $203 |
| Novartis Pharmaceuticals Corporation | 3 | $202 |
| Amgen Inc. | 4 | $152 |
| AKEBIA THERAPEUTICS INC | 2 | $140 |
| Ardelyx, Inc. | 9 | $138 |
| Novo Nordisk Inc | 1 | $114 |
| Travere Therapeutics, Inc. | 7 | $110 |
| Fresenius USA Marketing, Inc. | 5 | $101 |
| Lilly USA, LLC | 4 | $82 |
Products named: TARPEYO, JYNARQUE, Vanrafia, TAVNEOS, Vafseo, IBSRELA, Ozempic, VELPHORO.
Industry payments across IN — which companies pay providers there.
